

1 **Implementing a consultation service for translating genomic research findings into the**
2 **clinic: lessons from the SickKids Genome Board**

3
4 Amy Pan, MSc¹

5 Kenzie Pulsifer, MA¹

6 Michelle Axford, PhD, FCCMG^{2,3}

7 Lena Dolman, MD⁴

8 Bailey Gallinger, MSc, CGC^{5,6}

9 Eriskay Liston, MS, CGC^{6,7}

10 Elizabeth Stephenson, MSc, MD^{4,8,9}

11 Anna Szuto, MSc, CCGC^{1,5,6,7}

12 Laura Zahavich, MSc, CGC^{5,6,8}

13 Gregory Costain, MD, PhD^{1,4,5,6}

14

15 ¹Program in Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada

16 ²Genome Diagnostics, Department of Paediatric Laboratory Medicine, The Hospital for Sick
17 Children, Toronto, ON, Canada

18 ³Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON,
19 Canada

20 ⁴Department of Paediatrics, University of Toronto, Toronto, ON, Canada

21 ⁵Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON,
22 Canada

23 ⁶Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada

24 ⁷Precision Child Health, The Hospital for Sick Children, Toronto, ON, Canada

25 ⁸Division of Cardiology, The Hospital for Sick Children, Toronto, ON, Canada

26 ⁹SickKids Research Ethics Board, The Hospital for Sick Children, Toronto, ON, Canada

27

28 **Corresponding author:** Gregory Costain, gregory.costain@sickkids.ca, The Hospital for Sick
29 Children, 555 University Avenue, Toronto, ON, M5G 1X8, 416-813-7654 X301480

30

31 **Keywords:** genetic testing; genetic counseling; genome sequencing

32

33 **Acknowledgements and funding:** We thank the research teams at SickKids for submitting
34 questions to the Genome Board, and ad hoc Genome Board members for their input on specific
35 submissions. Funding for genetic counselling and administrative support was provided by
36 Novartis

1 **ABSTRACT**

2 **Objectives:** Genome-wide sequencing (GWS) is now used across the breadth of paediatric
3 research. There is a greater potential to identify unexpected, clinically relevant findings with
4 GWS than with the targeted genetic techniques used in prior decades. Individual research teams
5 may not have the expertise to evaluate and manage these findings. The Hospital for Sick
6 Children (SickKids) Genome Board is a no-cost consultation service for researchers with
7 questions arising from genetic aspects of their studies.

8 **Methods:** We reviewed all submissions to and recommendations from the Genome Board over
9 the first four years, to identify common questions, themes, and trends.

10 **Results:** There were 67 submissions, and a year-over-year increase in volumes. The most
11 common request (60%) was to assess variants identified by GWS for pathogenicity, clinical
12 actionability, and returnability to a study participant. Overall, 23 of 48 reviewed variants were
13 recommended for clinical confirmation and return with genetic counselling. Other categories of
14 submissions included requests to researchers from study participants to release their “raw”
15 genomic data, and for input on protocols related to clinical translation of findings.

16 **Conclusion:** The Genome Board provides a generalizable model for centralized triage of clinical
17 questions arising from genomic research at a paediatric centre. Clinicians should be aware that
18 patient participation in genetic research studies can have downstream consequences for their
19 healthcare.

1 INTRODUCTION

2 Genome-wide sequencing (GWS), including both exome sequencing and genome sequencing, is
3 now widely used in paediatric research (1–5). GWS has the potential to identify findings of
4 possible or definite clinical relevance (1,6,7). These may be “primary” results (i.e., relevant to
5 the phenotype under investigation), or “secondary” (6) or “incidental” (8) results (i.e.,
6 unexpected non-primary results that are intentionally or unintentionally identified, respectively).
7 Professional societies (e.g., American College of Medical Genetics and Genomics [ACMG]) and
8 large-scale community resources (e.g., Clinical Genome Resource [ClinGen]; Global Alliance
9 for Genomics & Health [GA4GH]) provide guidance on research best practices (9), variant
10 classification (10,11), disease-gene associations (11), and clinical actionability (11,12). Genetics
11 care providers like medical geneticists, genetic counsellors, and clinical laboratory directors have
12 expertise in interpreting and managing GWS results (7). In contrast, individual research groups
13 may not have the up-to-date training and knowledge to safely navigate the landscape of clinical
14 translatability (13).

15
16 At our institution (The Hospital for Sick Children; SickKids®), a significant and growing
17 number of active research studies involve the use of GWS. The Research Ethics Board (REB)
18 recognized the need for studies utilizing advanced genomic technologies to have an established
19 pathway to manage potential findings. In response, the Genome Board (comprised of authors
20 M.A., G.C., E.L., E.S., A.S.), was created in 2020 to offer a no-cost consultation service for
21 researchers at SickKids seeking advice on issues relating to genomic research. The Genome
22 Board aims to ensure consistency and transparency of genomic research practices, through
23 streamlining access to recommendations regarding potential clinical relevance of specific

1 genomic findings, and through promoting genomic research result confirmation and disclosure
2 that meet clinical standard of care. The Board's members have complementary expertise in
3 clinical genetics, molecular and laboratory genetics, genetic counselling, and research ethics,
4 with ad-hoc subject matter experts invited when needed to participate in specific case reviews.

5
6 The specific activities and overall impact of the Board have not been previously described. In
7 this study we describe the submissions to, and resulting feedback and recommendations from,
8 the Board over a four-year period. Given the increasing use of genetic technologies in research,
9 the implementation of a genomic review group at the institutional level can provide a valuable
10 service to researchers seeking support for emerging challenges and questions that arise from
11 genomic studies.

12 13 **METHODS**

14 This is a retrospective, single-centre cohort study approved by the REB at The Hospital for Sick
15 Children. The Genome Board accepts any inquiries, general or specific, from researchers across
16 the institution. Inquiries are made via an online submission form on Microsoft Power Apps.
17 Submitting researchers include de-identified study participant information, and copies of their
18 REB-approved protocols and consent forms, when needed. All information received from case
19 submissions is stored in a Microsoft SharePoint list accessible only to members of the Board.
20 The Genome Board meets monthly to review case submissions and generate
21 feedback/recommendations to return to the submitting research team. Input from additional ad-
22 hoc Board members with specific areas of expertise (e.g., cardiac genetics, cancer genetics) is
23 solicited when needed. All submissions are reviewed by one member of the Board upon

1 submission, prior to the monthly meeting. This pre-review can determine if the case may be
2 urgent thus requiring ad-hoc full review prior to the scheduled meeting, if more information
3 should be requested from the submitting team prior to full review, and if other expertise relevant
4 to the request should be consulted and/or invited to attend meetings.

5

6 A summary of the Board’s feedback and recommendations is shared directly with each
7 submitting research team and stored in the Microsoft SharePoint list. The following disclaimer is
8 included with the written recommendations: “During the meeting, members of the Genome
9 Board provided feedback related to queries posed by the submitting groups. This feedback was
10 based on the information provided to them before and during the meeting. Names and other
11 identifying data for specific research participants were purposefully NOT solicited. Genome
12 Board members did not have access to medical records or other collateral history. Genome Board
13 members did not have the opportunity to interview individuals about their personal and family
14 histories, nor to perform physical examinations. For these reasons, a medical opinion could not
15 be, and was not, provided. Genome Board members do not assume responsibility for any aspect
16 of the research participant’s medical care. Where discussion was based around findings from a
17 specific research study, Genome Board members did not have access to the entirety of this
18 research data. Interpretation of genomic findings is based on current knowledge and can change
19 over time.”

20

21 All case submissions received by the Genome Board since its inception (November 2020) to
22 August 2024 were included in this study. Standard descriptive and summary statistics were

- 1 calculated using Microsoft Excel. Qualitative data were collected using a content analysis
- 2 approach to identify categories and common themes across all case submissions.

3 **RESULTS**

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Type of Request	Case Summary	Genome Board Recommendations
Review of secondary or incidental variant for actionability & return	<p>A child was recruited into a non-cardiac-focused research study that included the use of singleton (child only) exome sequencing. The consent form indicated that participants could be told about medically actionable additional findings. In the course of reviewing variants annotated as "known pathogenic" in the ClinVar database, the genome analyst identified a "likely pathogenic" variant in the <i>RYR2</i> gene associated with catecholaminergic polymorphic ventricular tachycardia (CPVT). There was no documented personal or family history of cardiac issues in the records available to the study team.</p> <p>The Genome Board was consulted to provide guidance on whether to return this finding, and regarding next steps for the participating family.</p>	<p>The Genome Board recommended that this finding be returned to the family urgently. The Board agreed with the variant classification, and identified clear actionable next steps that can mediate high-risk cardiac manifestations. The Board recommended clinical confirmation of the variant and a referral to Cardiology to initiate diagnostic investigations. From a genetic counseling perspective, the Board recommended discussing generally that a variant related to heart rhythm differences was found, urging caution and against usage of the term "CPVT" to avoid causing significant anxiety in the family while the initial next steps are arranged.</p> <p>Impact: An urgent referral to Cardiology to initiate an exercise stress test that will clarify this patient's risk for CPVT, where manifestations can include syncope and sudden cardiac death. Confirmation of the diagnosis and variant would enable cascade testing of family members also at risk, including the proband's parents.</p>
Participant request for genomic data access	<p>A child with a neurodevelopmental disorder underwent research-based trio (child and biological parents) genome sequencing. The study team had completed their analyses and not identified diagnostic/potentially returnable variants. The child did not have capacity to consent at the time of recruitment (the parents provided consent on the child's behalf), and it was unclear to the study team if the child would ever gain capacity in the future. The parents requested that the research team send "all" the genome sequencing data to both their new care provider and to a research group, both located in another country.</p> <p>The Genome Board was consulted to provide guidance on if and how to release these data.</p>	<p>The Genome Board advised that participants have the right to their own genomic data and thus can request these data. Prior to sharing of data, consent is needed from all involved individuals and/or substitute decision makers (SDMs). In this case, the study team was advised to obtain new consent for both parents and for the child. Template documents for consent forms for data release requests are available at SickKids for study teams. The Board also advised that genomic data sharing should ideally occur through secure file transfer from SickKids directly to the requesting clinician or researcher.</p> <p>Impact: A secure release of genomic data to other clinicians and researchers enables further investigations that may benefit the patient. Informed re-consent of all individuals regarding the release of data specifically is important to uphold autonomy, as consenting to participate in a genetic research study does not assume consent to share one's genetic information elsewhere, even if for the purposes of care.</p>
Review of variant related to primary diagnosis	<p>A youth with a complex and unexplained medical issue underwent research-based genome-wide sequencing, as one component of a study focused in discovering new causes of this medical issue. The sequencing identified a rare DNA variant, in a gene ("A") that has not yet been definitively associated with human disease but that is related to a different gene ("B") associated with these medical issues.</p> <p>The Genome Board was consulted to provide guidance on the potential for this variant to be a primary diagnostic finding for the participant, and whether to return the result to the participant.</p>	<p>The Genome Board reviewed the available literature for gene A and classified it as a "candidate gene," defined as a gene with emerging evidence for an association with a disease phenotype that has not been formally established by curation resources (e.g. ClinGen). Thus, the Board did NOT recommend presenting the variant to the family as a diagnosis. Further exploration of this variant and gene in a research setting (e.g. functional assays, gene-matchmaker services) may generate additional evidence that helps to confirm or refute a gene-disease association.</p> <p>Impact: Informed recommendations against returning a result without established disease association ensures that only research findings with the highest likelihood for clinical relevance are returned to families and able to potentially impact clinical care.</p>

Table 1. Case vignettes and outcome recommendations made by the Genome Board, informed by real case submissions but with key details changed to protect patient confidentiality.

1

2 **Genome Board submissions reflected a breadth of issues pertaining to genomic research**

3 From November 1, 2020, to August 1, 2024, the Genome Board received and reviewed 67
4 submissions. There was a year-over-year increase in volumes (Figure 1a). Submissions were
5 made by 17 different individuals across 13 different research groups. The research groups were
6 studying conditions including but not limited to developmental, neurological, rheumatological,
7 renal, and cardiac disorders. One large-scale autism genomics research study made a majority of
8 the submissions (n=38, 57%) (4).

9

10 There were five main categories of submissions: (i) review of potential secondary or incidental
11 finding for clinical actionability and returnability (n=40 submissions, 60%; 43 different variants),
12 (ii) review of study participant access request for “raw” genomic data (n=9, 13%; including n=1
13 hypothetical and n=8 actual requests) (14), (3) review of potential primary finding for clinical
14 actionability and returnability (n=8, 12%; 8 different variants), (4) query about general genomic
15 research best practices (n=6, 9%), and (5) review of proposed genomic study design (n=4, 6%).

16 Box 1 includes three representative case vignettes.

17

18 **Recommendations regarding returnability of DNA variants were case-dependent**

19 Variants in 47 different genes (submitted as either a primary, secondary, or incidental finding)
20 were reviewed by the Board. The most common phenotypic category of genes submitted for
21 review was cardiovascular (n=12, 26%; e.g., cardiomyopathy, arrhythmia). Multiple variants were
22 submitted for four genes (*BRCA2*, *CLCN1*, *MFN2*, *RNF213*). Nine genes (19%) were on the
23 ACMG Secondary Findings v3.2 gene list (12), and 17 genes (36%) had been assessed for

1 paediatric and/or adult actionability by ClinGen (11). The Genome Board recommended
2 returning 23 (48%) findings to participants/families, conditionally returning 8 (17%) findings
3 (e.g., return if patient not previously assessed for condition X or not previously seen by specialist
4 Y), and against returning 20 (42%) findings.

5
6 The Board considered the following lines of evidence in making recommendations for return of
7 the 23 findings: (i) variant classification (e.g., pathogenic or likely pathogenic), (ii) medical
8 actionability (e.g., clear guidelines for management and/or screening for individuals at-risk for,
9 or diagnosed with, the associated condition), and (iii) implications for family members (e.g.,
10 initiation of cascade testing or screening for relatives). Reasons not to return findings included:
11 (i) unclear disease association (e.g., weak or unclear gene- or variant-disease association,
12 including candidate genes), (ii) unclear or lack of medical actionability (e.g., no guidelines or
13 evidence for management and/or screening, including evidence indicating that management
14 would not change), (iii) uncertain variant classification (conflicting or insufficient evidence for
15 variant pathogenicity) (15), and (iv) poor phenotype fit for variant to be a primary diagnostic
16 finding.

17

18 **Other considerations raised in the context of paediatric genomic research**

19 An additional 8 (14%) of the initial submissions had potential for direct participant impact
20 (“actionability”) in the form of requests for data release. The Genome Board recommended
21 releasing data to participants for 7 (88%) and against releasing data for 1 (12%), as the family
22 requested access to information that was not permitted in accordance with data governance

1 policies. A one-page consent form template for return of genomic data is available from our
2 institution upon request.

3
4 With respect to submissions relating to genomic research best practices and study design,
5 feedback from the Genome Board included the sharing of existing resources (e.g., from ACMG,
6 ClinGen, REB, institutional legal services) and recommendations to include / exclude certain
7 elements in protocol designs (e.g., specific language use in consent forms (16)).

8

9 **DISCUSSION**

10 The Genome Board is a genomics consultation service developed and implemented at SickKids
11 in late 2020. Over a four-year period, the Genome Board received and reviewed 67 submissions
12 from a diverse group of intra-institutional research teams seeking guidance on issues related to
13 genomic research. Genomic research can and often does generate findings that warrant
14 downstream clinical attention. Resolution of queries and formulation of feedback/
15 recommendations required consideration of principles including but not limited to: variant
16 classification and gene-disease association, genotype-phenotype correlation, medical
17 actionability, and research and clinical ethics considerations (e.g., rights to owning one's data,
18 patient autonomy and informed consent, protection of patient privacy).

19

20 **The Genome Board offers a valuable and increasingly utilized service to institutional**
21 **research groups by guiding the resolution of challenges associated with genomic research**

22 Since its inception, the Genome Board has been utilized increasingly across multiple disciplines
23 within the institution. The gradual implementation of genomic components into more research

1 protocols results in more genomic-related queries and concerns that may fall out of the scope of
2 the organizing team. Targeted promotional efforts within the institution has increased visibility
3 and awareness of the Genome Board, and repeated submissions from the same submitting team
4 may indicate satisfaction with and trust in the service offered. These results demonstrate a
5 growing interest in and need for a genomics consultation service, and we suspect a similar
6 demand at other paediatric academic institutions. In this study, most submitting research teams
7 did not have the volume of questions to justify significant investment in their own study-specific
8 genomics review group. The availability and accessibility of genomics expertise on an
9 institutional level may empower research teams to incorporate genomic components into their
10 study designs.

11
12 The Genome Board has specifically provided guidance on many research findings of potential
13 actionability. Secondary findings are a recurrent notable potential benefit — or burden —
14 derived from GWS (17,18). The current clinical standard of the ACMG is to report known or
15 predicted disease-causing variants in genes that cause medically actionable and highly penetrant
16 conditions. Guidelines, however, cannot assess whether specific additional findings (either
17 “secondary” or “incidental”) discovered by a research group meet the threshold for returnability
18 to families and, if so, the appropriate next steps for the variant or counselling approaches for
19 result disclosure. Furthermore, the advent of technology and migration of health information
20 onto electronic-based medical systems may lead to greater desire for and capacity to access one’s
21 own healthcare data. Genomic data, in particular because of its inherent identifiability, warrants
22 greater caution to protect privacy. Developing consistent policies for the release of genomic data,
23 including the establishment of appropriate informed consent procedures, will be an important

1 focus for research groups moving forward as the number of such requests from participants
2 increases. The submissions to the Genome Board highlight the importance of developing local,
3 provincial/territorial, and/or national guidelines to address recurrent issues related to genomic
4 research, to ensure consistency and transparency in practice.

5
6 Our study has several limitations. The submissions received at SickKids may not be
7 representative of the questions and challenges at other institutions. Questions about the
8 amenability of DNA findings to pharmacogenetics (19) or genetic therapy development (20,21)
9 are expected to increase in the coming years. The outcomes of cases following the return of
10 recommendations were unknown. Specifically, we were unable to confirm if the Genome
11 Board's recommendations were followed by the study team, the level of submitter satisfaction
12 with the service provided, or if additional informative patient information was discovered during
13 or after the review process. The Genome Board's recommendations with respect to a specific
14 variant or query may change over time. However, one author (A.P.) re-reviewed all submissions
15 during the drafting of this manuscript, and there were none where the variant interpretation
16 and/or rationale for/against a specific recommendation had changed enough to warrant re-review
17 by the Board.


18
19 In summary, implementing a consultation service for translating genomic research findings into
20 the clinic at a large pediatric academic centre was necessary, feasible, and required minimal
21 resources beyond expert volunteers. The Genome Board is one model for adjudicating and
22 providing guidance for queries relating to genomic research, through leveraging expertise from
23 clinical areas. Improving the quality of institutional genomic research practice and enabling

1 findings to appropriately impact care outcomes can benefit researchers, care teams, and
2 participants and their families. Precision Child Health (22) and other large-scale genomics-
3 related initiatives in paediatrics will necessitate enhanced coordination between clinical and
4 research services, particularly as genomic data is increasingly sought after, generated, and
5 validated for use in care.
6

1 REFERENCES

- 2 1. Costain G, Walker S, Marano M, Veenma D, Snell M, Curtis M, et al. Genome
3 Sequencing as a Diagnostic Test in Children With Unexplained Medical Complexity. *JAMA*
4 *Network Open*. 2020 Sep 22;3(9):e2018109.
- 5 2. Hayeems RZ, Boycott KM. Genome-wide sequencing technologies: A primer for
6 paediatricians. *Paediatr Child Health*. 2018 May;23(3):191–7.
- 7 3. Boycott KM, Hartley T, Kernohan KD, Dymont DA, Howley H, Innes AM, et al.
8 Care4Rare Canada: Outcomes from a decade of network science for rare disease gene discovery.
9 *American Journal of Human Genetics*. 2022 Nov 3;109(11):1947.
- 10 4. Trost B, Thiruvahindrapuram B, Chan AJ, Engchuan W, Higginbotham EJ, Howe JL, et
11 al. Genomic Architecture of Autism From Comprehensive Whole-Genome Sequence
12 Annotation. *Cell*. 2022 Nov 10;185(23):4409.
- 13 5. Elliott AM, Adam S, Souich C du, Lehman A, Nelson TN, Karnebeek C van, et al.
14 Genome-wide sequencing and the clinical diagnosis of genetic disease: The CAUSES study.
15 *Human Genetics and Genomics Advances*. 2022 Apr 18;3(3):100108.
- 16 6. Majeed S, Johnston C, Saedi S, Mighton C, Rokoszak V, Abbasi I, et al. International
17 policies guiding the selection, analysis, and clinical management of secondary findings from
18 genomic sequencing: A systematic review. *The American Journal of Human Genetics*. 2024 Oct
19 3;111(10):2079–93.
- 20 7. Costain G, Cohn RD, Scherer SW, Marshall CR. Genome sequencing as a diagnostic test.
21 *CMAJ* □: *Canadian Medical Association Journal*. 2021 Oct 25;193(42):E1626.
- 22 8. Middleton A, Morley KI, Bragin E, Firth HV, Hurles ME, Wright CF, et al. Attitudes of
23 nearly 7000 health professionals, genomic researchers and publics toward the return of incidental
24 results from sequencing research. *European Journal of Human Genetics*. 2015 Apr 29;24(1):21.
- 25 9. Lewis ACF, Knoppers BM, Green RC. An international policy on returning genomic
26 research results. *Genome Med*. 2021 Jul 15;13(1):115.
- 27 10. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and
28 Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of
29 the American College of Medical Genetics and Genomics and the Association for Molecular
30 Pathology. *Genetics in medicine* □: official journal of the American College of Medical Genetics.
31 2015 Mar 5;17(5):405.
- 32 11. Andersen EF, Azzariti DR, Babb L, Berg JS, Biesecker LG, Bly Z, et al. The Clinical
33 Genome Resource (ClinGen): Advancing genomic knowledge through global curation. *Genetics*
34 *in Medicine*. 2024 Oct 15;101228.
- 35 12. Miller DT, Lee K, Abul-Husn NS, Amendola LM, Brothers K, Chung WK, et al. ACMG
36 SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A
37 policy statement of the American College of Medical Genetics and Genomics (ACMG). *Genetics*
38 *in medicine* □: official journal of the American College of Medical Genetics. 2023 Jun
39 22;25(8):100866.
- 40 13. Wynn J, Martinez J, Duong J, Zhang Y, Phelan J, Fyer A, et al. Association of researcher
41 characteristics with views on return of incidental findings from genomic research. *Journal of*
42 *genetic counseling*. 2015 Jan 17;24(5):833.
- 43 14. Chad L, Szego MJ. Please give me a copy of my child’s raw genomic data. *NPJ Genomic*
44 *Medicine*. 2021 Feb 17;6:15.
- 45 15. Joynt ACM, Axford MM, Chad L, Costain G. Understanding genetic variants of
46 uncertain significance. *Paediatrics & Child Health*. 2021 Sep 13;27(1):10.

- 1 16. Longstaff H, Flamenbaum J, Richer E, Egar J, McMaster CR, Zawati MH. Core elements
2 of participant consent documents for Canadian human genomics research and the National
3 Human Genome Library: guidance for policy. *CMAJ*. 2022 Nov 15;194(44):E1500–8.
- 4 17. Mackley MP, Fletcher B, Parker M, Watkins H, Ormondroyd E. Stakeholder views on
5 secondary findings in whole-genome and whole-exome sequencing: a systematic review of
6 quantitative and qualitative studies. *Genetics in Medicine*. 2016 Sep 1;19(3):283.
- 7 18. Saeidian AH, March ME, Youssefian L, Watson DJ, Bhandari E, Wang X, et al.
8 Secondary ACMG and non-ACMG genetic findings in a multiethnic cohort of 16,713 pediatric
9 participants. *Genet Med*. 2024 Jul 31;26(11):101225.
- 10 19. Pan A, Scodellaro S, Khan T, Ushcatz I, Wu W, Curtis M, et al. Pharmacogenetic
11 profiling via genome sequencing in children with medical complexity. *Pediatric Research*. 2022
12 Sep 27;93(4):905.
- 13 20. Lauffer MC, Roon-Mom W van, Aartsma-Rus A, Collaborative N= 1. Possibilities and
14 limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders.
15 *Communications Medicine*. 2024 Jan 5;4:6.
- 16 21. Cheerie D, Meserve M, Beijer D, Kaiwar C, Newton L, Tavares ALT, et al. Consensus
17 guidelines for eligibility assessment of pathogenic variants to antisense oligonucleotide
18 treatments. *medRxiv*. 2024 Jan 1;2024.09.27.24314122.
- 19 22. Howell KB, White SM, McTague A, D’Gama AM, Costain G, Poduri A, et al. Precision
20 Child Health: accelerating discovery and improving outcomes in rare pediatric disease. *NPJ*
21 *Genomic Medicine*. In revision;
22



1
2 **Figure 1. Timing and outcomes of submissions received by the SickKids Genome Board.**
3 Created with BioRender.com. (a) Number of submissions received by the Genome Board per
4 year since its inception. No submissions were received in November 2020 or December 2020.
5 For this report, only submissions until August 1, 2024, were included. (b) Outcome
6 recommendations for submissions that were determined to have potential for actionability. See
7 text for detail.